Xiren

Siren Biotechnology is a clinical-stage biotechnology company pioneering a novel therapeutic modality known as AAV immuno-gene therapy. By combining the precision of adeno-associated virus (AAV) gene delivery with the potency of cytokine immunotherapy, the company aims to transform the treatment landscape for solid tumors. Its lead candidate, SRN-101, is designed to deliver an engineered cytokine locally within the tumor environment to stimulate a robust anti-tumor immune response. Siren is initially focusing on recurrent high-grade glioma, a devastating form of brain cancer with significant unmet medical need. The company's vision is for its universal immuno-gene therapy platform to become a cornerstone treatment for a wide range of solid tumor indications.